# OnCo record nct05112965 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05112965/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05112965", "NCT05112965" ;
  schema:name "An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)"@en ;
  schema:alternateName "IMbrella C"@en ;
  schema:description "A phase 3 trial of Atezolizumab, Bevacizumab, Pemetrexed and Enzalutamide in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05112965/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05112965> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-12-01" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/enzalutamide/> ;
  onco:companies <https://onco.cc/companies/flatiron-health/> .